ClinicalTrials.gg
CompletedNCT05378893Updated Oct 19, 2026Results posted

A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624

A Phase 1 interventional study of DR10624 for injection and Placebo in Healthy, Obesity, Metabolically, sponsored by Zhejiang Doer Biologics Co., Ltd.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Zhejiang Doer Biologics Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 19, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.

Read the detailed description

This study includes 2 parts( 1 and 2). Part 1 involves a single dose of DR10624 taken as a subcutaneous injection just under the skin. Part 2 involve multiple doses of DR10624 taken as a subcutaneous injection (SC) just under the skin. Each participant will enroll in only one part.

02

Conditions studied

  • Healthy, Obesity, Metabolically
03

In context

Obesity, Metabolically Benign

27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.

This study's enrollment of 153 is above the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.

Browse Obesity, Metabolically Benign studies →

Lead sponsor

Zhejiang Doer Biologics Co., Ltd. is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

First submitted after Zhejiang Doer Biologics Co., Ltd. became part of Huadong Medicine Co., Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening.
  2. Female subjects (heterosexually active, of , not pregnant, not trying to become pregnant, and not lactating) are eligible to participate if they agree to total abstinence from heterosexual intercourse or use a highly effective method of listed below, from screening through until at least 30 days after the last dose of the study drug.

    Male subjects with female partners of childbearing potential are eligible to participate if they are vasectomized, or agree to total abstinence from heterosexual intercourse, from screening through until at least 30 days after the last study dose, or use of an effective method of birth control listed above, from screening through until at least 30 days after the last study dose. Male subjects must refrain from sperm donation throughout the study and for 30 days after the last study dose.

  3. The subject agrees to comply with all protocol requirements.
  4. The subject is able to provide written .

Additional inclusion criteria for Part 1:

  1. The subject is male or female 18 to 55 years of age, inclusive.
  2. The subject has a body weight ≥50 kg at screening and a of 18 to 32 kg/m2, inclusive, or.
  3. The subject has a BMI of 30 to 40 kg/m2, inclusive, at screening in obesity subjects cohort.

Additional inclusion criteria for Part 2:

  1. The subject is male or female 18 to 60 years of age, inclusive.
  2. The subject has a BMI of 30 to 45 kg/m2 at screening, inclusive.
  3. Fasting triglyceride ≥150 mg/dL (1.7 mmol/L), and \<500 mg/dL (5.7 mmol/L), at screening.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a positive test result for surface antigen, virus antibody, or types 1 or 2 antibodies at screening.
  2. The subject has a personal or family history of medullary thyroid cancer, or multiple endocrine neoplasia syndrome Type 2, or a screening calcitonin ≥50 ng/L.
  3. The subject has a history of chronic pancreatitis or episode of acute pancreatitis within 3 months of screening.
  4. In Part 1, the subject has used any prescription medications (excluding oral , paracetamol, and ibuprofen) within 14 days before the first dose of study drug. In Part 2, the subjects have been on stable lipid-lowering therapy \<8 weeks before the first dose of study drug.
  5. The subject has consumed alcohol within 48 hours before dosing or during the confinement period.
  6. The subject is a smoker or has used tobacco, nicotine, or nicotine-containing products.
  7. The subject has a history of alcohol abuse or drug addiction within the last year or excessive alcohol consumption.
  8. The subject has a positive test result for drugs of abuse and/or alcohol abuse at screening and check-in for the first inpatient period.
  9. The subject is involved in strenuous activity or contact sports within 48 hours before admission.
  10. The subject has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
  11. The subject has total cholesterol >10.3 mmol/L or triglycerides ≥5.7 mmol/L (500 mg/dL) at screening.
  12. The subject has history or presence of findings as determined by the investigator at screening and check-in,

    - Uncontrolled hypertension (defined as systolic blood pressure (SBP) ≥160 mmHg, and/or diastolic blood pressure (DBP) ≥100 mmHg), angina, bradycardia (if assessed as clinically significant by the investigator), or severe peripheral arterial circulatory disorders.

  13. The subject has a history of relevant drug and/or food allergies (ie, allergy to DR10624 or , or any significant food allergy that could preclude a standard diet in the clinical unit).
  14. The subject has a history of severe allergic or anaphylactic reactions.
  15. The subject has experienced a >5% loss in body weight within 2 months prior to screening.
  16. Female subjects who are pregnant or lactating.
  17. The subject has a positive test for severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). A positive rapid antigen test (RAT), isothermal nucleic acid amplification, or polymerase chain reaction (PCR) coronavirus disease-2019 (COVID-19) test during screening or at admission is acceptable provided the subject has a known previous COVID-19 infection ≥3 weeks prior to dosing, has recovered, and is now asymptomatic
  18. The subject has received study drug in another study within 30 days of dosing.
  19. In the opinion of the investigator, the subject is not suitable for entry into the study.

Additional exclusion criteria for subjects in Part 2:

  1. Subjects with coagulopathies.
  2. Poorly controlled diabetes, defined as >8.5% at screening.
  3. The subject has been treated with the following anti-diabetic agents, glucagon-like peptide-1 receptor agonist (GLP-1Ra), dipeptidyl peptidase-4 inhibitors (DPP-4i), or insulin, within 30 days prior to screening until the follow-up visit.
  4. The subjects have >2 × (ULN) of either (ALT) or aspartate aminotransferase (AST), or >1.5 × ULN for or alkaline phosphatase at screening.
  5. Subjects with to MRI.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Single-ascending dose:Part1:DR10624

    Escalating doses of DR10624 for injection administered subcutaneously in healthy participants or obese but otherwise healthy participants

    Drug: DR10624 for injection

  • Placebo comparator
    Single-ascending dose:Part1:placebo

    Escalating doses of placebo for injection administered subcutaneously in in healthy participants or obese but otherwise healthy participants

    Drug: Placebo

  • Experimental
    Multiple-ascending dose:Part2:DR10624

    Escalating doses of DR10624 for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia

    Drug: DR10624 for injection

  • Placebo comparator
    Multiple-ascending dose:Part2:placebo

    Escalating doses of placebo for injection administered subcutaneously in obese adult subjects with moderate hypertriglyceridemia

    Drug: Placebo

  • Experimental
    Single-ascending dose:Part3:DR10624

    A SAD part in Chinese healthy adult subjects or overweight or obese adults but otherwise healthy adult subjects.

    Drug: DR10624 for injection

  • Placebo comparator
    Single-ascending dose:Part3:placebo

    A SAD part in Chinese healthy adult subjects or overweight or obese adults but otherwise healthy adult subjects.

    Drug: Placebo

Interventions

  • administered via subcutaneous injection

  • DrugPlacebo

    administered via subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Assess the Safety and Tolerability

    Area under the serum concentration-time curve (AUC). For Part 1 and Part 3, AUC from time 0 to infinity (AUC0-inf) is presented. For Part 2, AUC over the dosing interval (AUC0-tau) assessed from pre-dose on Day 78 to 168 hours post-dose is presented. Data presented are from baseline through Day 29 (Part 1 and Part 3) and from pre-final dose on Day 78 through Day 106 (Part 2)

    Time frame: Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)

Secondary outcomes

  1. Area Under the Serum Concentration Versus Time Curve (AUC)

    The area under the serum concentration versus time curve from Time 0 to Time t (AUC0-t), which is calculated over the following time frames: baseline through Day 29 for Part 1 and Part 3; for Part 2, from pre-dose of the final dose on Day 78 to post-dose Day 106 (Day 29 after the final dose).

    Time frame: baseline through day 29 (part 1and part 3)or day 106 (part 2)

  2. Maximum Observed Serum Concentration (Cmax)

    Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

    Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)

  3. Time to Reach Maximum Observed Serum Concentration (Tmax)

    Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

    Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2).

  4. Terminal Elimination Half-life (t1/2)

    Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

    Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2).

  5. Apparent Clearance After Extravascular Administration (CL/F)

    Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

    Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)

  6. Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F)

    Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

    Time frame: baseline through day 29 (part 1and part 3) or day 106 (part 2)

  7. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)

    Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)

    Time frame: baseline through day29(part 1 and part 3 )

  8. Change in Body Weight

    the difference in LS Means body weight change from baseline compared with placebo

    Time frame: baseline through Day 85(part 2)

  9. Change in Adiponectin

    the difference in LS Means adiponectin change from baseline compared with placebo

    Time frame: baseline through Day 85

  10. the Difference in LS Means BMI Change From Baseline Compared With Placebo

    change in BMI

    Time frame: baseline through Day 85(part 2)

  11. the Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo

    change in waist circumference

    Time frame: baseline through Day 85(part 2)

  12. Change in Fasting Lipid Profile

    the difference in LS Means Ratio fasting lipid profile change from baseline compared with placebo

    Time frame: baseline through Day 85(part 2)

  13. Change in Fasting Plasma Glucose (FPG)

    the difference in LS Means FPG change from baseline compared with placebo

    Time frame: baseline through Day 85

  14. Change in C-peptide

    the difference in LS Means Ratio of C-peptide change from baseline compared with placebo

    Time frame: baseline through Day 85(part 2)

  15. Change in Fasting Insulin

    the difference in LS Means Ratio of fasting insulin change from baseline compared with placebo

    Time frame: baseline through Day 85(part 2)

  16. Change in Hemoglobin A1C

    the difference in LS Means Ratio of Hemoglobin A1C change from baseline compared with placebo

    Time frame: baseline through Day 85(part 2)

  17. Change in Glucagon

    the difference in LS Means Ratio fasting glucagon change from baseline compared with placebo

    Time frame: baseline through Day 85

  18. Change in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B)

    The difference in LS Means Ratio HOMA-IR and HOMA-B change from baseline compared with placebo. HOMA-IR: (Fasting Insulin \[μU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5; HOMA-β: (20 × Fasting Insulin \[μU/mL\]) / (Fasting Glucose \[mmol/L\] - 3.5). For HOMA-IR: lower values indicate improved insulin sensitivity (less insulin resistance), representing a better outcome. For HOMA-B: higher values indicate enhanced pancreatic beta-cell function, representing a better outcome.

    Time frame: baseline through Day 85

  19. Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2

    percentage change from baseline in hepatic fat fraction measured by MRI-PDFF in part 2. Percent change was calculated as \[(post-baseline value - baseline value) / baseline value\] × 100.

    Time frame: Baseline (screening) and Day 85 to Day 99 in Part 2

  20. Positive Rate of ADA

    overall positive rate of ADA at EOS

    Time frame: from baseline to the end of the study, up to Day29s (part1, part3), up to Day106s (part2)

  21. Continuous Glucose Monitoring Outcome

    Individual results of CGM endpoints and results are presented by subject in the listing contained in the CSR attachment.

    Time frame: from baseline to D79(part 2)

  22. Change in Fibrosis 4 Index

    Change in Fibrosis 4 Index from baseline. Fibrosis 4 Index (FIB-4) is a continuous calculated score for liver fibrosis staging, derived from the formula: FIB-4 = (age \[years\] × AST \[U/L\]) / (platelet count \[10\^9/L\] × √ALT \[U/L\]), which can be used to identify patients with a low probability of advanced fibrosis. The theoretical minimum value is 0, and there is no predefined maximum value (the score is open-ended). Lower values indicate a lower probability of advanced liver fibrosis, representing a better outcome. For clinical interpretation, commonly used cutoff values are as follows: FIB-4 \< 1.3: low probability of advanced liver fibrosis (better outcome); 1.3 ≤ FIB-4 \< 3.25: indeterminate fibrosis stage; FIB-4 ≥ 3.25: high probability of advanced liver fibrosis (worse outcome).

    Time frame: from baseline to D85(part 2)

  23. Change in Non-Alcoholic Fatty Liver Disease Fibrosis Score

    The Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) is a derived non-invasive fibrosis score calculated as -1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m\^2) + 1.13 × impaired fasting glucose or diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10\^9/L) - 0.66 × albumin (g/dL). This score does not have a fixed theoretical minimum or maximum; higher values indicate greater likelihood of advanced fibrosis

    Time frame: from baseline to D85 (part 2)

  24. Change in Alanine Aminotransferase

    change in Alanine Aminotransferase from baseline

    Time frame: from baseline to D85 (part 2)

  25. Change in Aspartate Aminotransferase

    change in Aspartate Aminotransferase from baseline

    Time frame: from baseline to D85 (part 2)

  26. Change in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

    change in Partial area glucose levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

    Time frame: from 0 to 4 hours on D79

  27. Change in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

    change in Partial area insulin levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

    Time frame: from 0 to 4 hours on D79

  28. Change in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

    change in Partial area C-peptide levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

    Time frame: from 0 to 4 hours on D79

  29. Change in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

    change in Partial area glucagon levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

    Time frame: from 0 to 4 hours on D79

  30. Change Percentage of Time Spent of Glucose in Target Range 3.9 to 10 mmol/L (TIR), Time Above Target Range (TAR), Time Below Target Range (TBR), 24-hour Mean Glucose, and Glucose Variability

    statistical analysis of TIR, TAR, TBR, 24-hour mean glucose and glucose variability was not performed due to small sample size

    Time frame: baseline through Day 85(part 2)

07

Results

Posted Oct 19, 2026

Participant flow

This was a randomised, double-blinded, parallel-design, placebo-controlled, multi-national, and multi-centre study with different DR10624 doses (Single-Ascending and Multiple-Ascending doses ranging from 1.5 mg/week to 120 mg/week) in patients with healthy or overweight to obese, and obese with modest hypertriglyceridemia.

Participant flow — Overall Study
MilestoneSingle-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part3:DR10624 65mgSingle-ascending Dose:Part3:DR10624 90mgSingle-ascending Dose:Part3:DR10624 25mgSingle-ascending Dose:Part3:Placebo
Started466666666161010111081010106
Completed46666666616998871010106
Not completed0000000000113210000
Withdrew: Adverse event0000000000010200000
Withdrew: Withdrawal by subject0000000000103000000
Withdrew: Other reason0000000000000010000

Outcome measures

PrimaryAssess the Safety and Tolerability

Area under the serum concentration-time curve (AUC). For Part 1 and Part 3, AUC from time 0 to infinity (AUC0-inf) is presented. For Part 2, AUC over the dosing interval (AUC0-tau) assessed from pre-dose on Day 78 to 168 hours post-dose is presented. Data presented are from baseline through Day 29 (Part 1 and Part 3) and from pre-final dose on Day 78 through Day 106 (Part 2)

Time frame:
Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)
Reported as:
Number · participants
Assess the Safety and Tolerability
participantsDR10624 0.5mg Part1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1Single-ascending Dose:Part1:PlaceboDR10624 12.5mg Part2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2Multiple-ascending Dose:Part2:PlaceboDR10624 25mg Part 3DR10624 65mg part3DR10624 90mg part3Single Ascending Dose :Part 3:Placebo
Any TEAE — Any TEAE454656655121010111077675
Any Treatment-Related TEAE — Any TEAE012336644468111055370
SecondaryArea Under the Serum Concentration Versus Time Curve (AUC)

The area under the serum concentration versus time curve from Time 0 to Time t (AUC0-t), which is calculated over the following time frames: baseline through Day 29 for Part 1 and Part 3; for Part 2, from pre-dose of the final dose on Day 78 to post-dose Day 106 (Day 29 after the final dose).

Time frame:
baseline through day 29 (part 1and part 3)or day 106 (part 2)
Reported as:
Geometric mean · h*ng/mL
Area Under the Serum Concentration Versus Time Curve (AUC)
h*ng/mLDR10624 0.5mg Part 1DR10624 1.5 mg Part 1DR10624 4.5 mg Part 1DR10624 12.5mg Part 1DR10624 25mg Part 1DR10624 50mg Part 1DR10624 65mg Part 1DR10624 90mg Part 1DR10624 120mg Part 1DR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2DR10624 25mg Part 3DR10624 65mg Part 3DR10624 90mg Part 3
Area Under the Serum Concentration Versus Time Curve (AUC)5000 ± 59.221800 ± 19.464200 ± 25.4266000 ± 35.4457000 ± 24.71360000 ± 32.7789000 ± 23.31020000 ± 29.81360000 ± 39.2223000 ± 43.9602000 ± 38.21000000 ± 19.31980000 ± 33.5245000 ± 49.3668000 ± 51.3976000 ± 30.2
SecondaryMaximum Observed Serum Concentration (Cmax)

Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

Time frame:
baseline through day 29 (part 1and part 3) or day 106 (part 2)
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentration (Cmax)
ng/mLDR10624 0.5mg Part 1DR10624 1.5mg part1DR10624 4.5mg Part 1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg part2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Maximum Observed Serum Concentration (Cmax)33.0 ± 53.8110 ± 35.5307 ± 46.91210 ± 53.82010 ± 29.85950 ± 43.43420 ± 35.23870 ± 32.47000 ± 54.7987 ± 37.52610 ± 42.14540 ± 22.67960 ± 35.21130 ± 68.22880 ± 72.44300 ± 39.9
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax)

Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

Time frame:
baseline through day 29 (part 1and part 3) or day 106 (part 2).
Reported as:
Median · h
Time to Reach Maximum Observed Serum Concentration (Tmax)
hDR10624 0.5mg part1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg Part 2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Time to Reach Maximum Observed Serum Concentration (Tmax)72.00 (48.03 to 72.00)48.00 (48.00 to 120.00)72.00 (48.00 to 96.00)72.00 (48.00 to 120.00)84.00 (48.00 to 96.00)72.00 (48.05 to 144.13)96.09 (48.00 to 120.00)96.00 (72.00 to 96.02)60.03 (24.02 to 168.00)48.06 (45.98 to 96.00)48.03 (46.13 to 96.47)95.98 (47.27 to 119.17)69.48 (47.87 to 96.10)72.02 (47.98 to 119.98)83.87 (47.78 to 240.03)72.00 (47.75 to 95.75)
SecondaryTerminal Elimination Half-life (t1/2)

Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

Time frame:
baseline through day 29 (part 1and part 3) or day 106 (part 2).
Reported as:
Geometric mean · h
Terminal Elimination Half-life (t1/2)
hDR10624 0.5mg Part 1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg Part 2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Terminal Elimination Half-life (t1/2)77.9 ± 33.377.3 ± 27.271.0 ± 17.081.0 ± 10.292.6 ± 11.889.5 ± 6.591.4 ± 10.886.0 ± 21.2107 ± 14.594.1 ± 20.2101 ± 11.7102 ± 13.7106 ± 11.780.1 ± 20.980.6 ± 14.494.7 ± 20.8
SecondaryApparent Clearance After Extravascular Administration (CL/F)

Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

Time frame:
baseline through day 29 (part 1and part 3) or day 106 (part 2)
Reported as:
Geometric mean · L/h
Apparent Clearance After Extravascular Administration (CL/F)
L/hDR10624 0.5mg part1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg Part 2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Apparent Clearance After Extravascular Administration (CL/F)0.0586 ± 21.80.0655 ± 18.50.0689 ± 25.00.0466 ± 34.80.0542 ± 24.30.0364 ± 32.70.0816 ± 23.30.0875 ± 29.70.0867 ± 38.50.0928 ± 36.40.0715 ± 35.70.0843 ± 23.30.0687 ± 29.40.101 ± 48.50.0965 ± 50.80.0910 ± 30.0
SecondaryApparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F)

Maximum observed serum concentration (Cmax). For Part 1 and Part 3, data are presented from baseline through Day 29. For Part 2, data after the final dose (administered on Day 78) are presented through Day 106. The time frame for data collection spans the entire study period for each part as indicated.

Time frame:
baseline through day 29 (part 1and part 3) or day 106 (part 2)
Reported as:
Geometric mean · L
Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F)
LDR10624 0.5mg Part 1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg Part 2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Apparent Volume of Distribution During the Terminal Elimination Phase After Extravascular Administration (Vz/F)5.53 ± 54.77.30 ± 35.87.06 ± 41.55.45 ± 42.97.24 ± 29.44.71 ± 33.010.8 ± 24.310.8 ± 39.713.4 ± 50.512.6 ± 30.910.4 ± 43.512.4 ± 33.110.6 ± 30.611.7 ± 71.811.2 ± 56.512.4 ± 38.3
SecondaryArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)

Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)

Time frame:
baseline through day29(part 1 and part 3 )
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
h*ng/mLDR10624 0.5mg Part 1DR10624 1.5mg part1DR10624 4.5mg Part 1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)8540 ± 12.822900 ± 18.565300 ± 25268000 ± 34.8461000 ± 24.31370000 ± 32.7797000 ± 23.21030000 ± 29.71380000 ± 38.5247000 ± 48.5247000 ± 50.8989000 ± 30
SecondaryChange in Body Weight

the difference in LS Means body weight change from baseline compared with placebo

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · kg
Change in Body Weight
kgDR10624 12.5mg part2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
Change in Body Weight2.594 (-2.279 to 7.466)0.603 (-4.272 to 5.477)-2.079 (-7.036 to 2.878)-1.279 (-6.230 to 3.673)
SecondaryChange in Adiponectin

the difference in LS Means adiponectin change from baseline compared with placebo

Time frame:
baseline through Day 85
Reported as:
Geometric least squares mean · mg/L
Change in Adiponectin
mg/LDR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
Change in Adiponectin-0.490 (-4.747 to 3.768)1.994 (-2.264 to 6.251)3.986 (-0.379 to 8.351)3.031 (-1.322 to 7.383)
Secondarythe Difference in LS Means BMI Change From Baseline Compared With Placebo

change in BMI

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · kg/m2
the Difference in LS Means BMI Change From Baseline Compared With Placebo
kg/m2DR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
the Difference in LS Means BMI Change From Baseline Compared With Placebo0.839 (-0.745 to 2.423)0.224 (-1.360 to 1.808)-0.873 (-2.486 to 0.740)-0.607 (-2.216 to 1.002)
Secondarythe Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo

change in waist circumference

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · cm
the Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo
cmDR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
the Difference in LS Means Waist Circumference Change From Baseline Compared With Placebo3.544 (-3.085 to 10.173)4.436 (-2.198 to 11.070)1.856 (-4.867 to 8.579)-0.503 (-7.229 to 6.222)
SecondaryChange in Fasting Lipid Profile

the difference in LS Means Ratio fasting lipid profile change from baseline compared with placebo

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · mmol/L
Change in Fasting Lipid Profile
mmol/LDR10624 12.5mg CholesterolDR10624 25 mg CholesterolDR10624 50 mg CholesterolDR10624 75mg CholesterolDR10624 12.5 mg LDL CholesterolDR10624 25 mg LDL CholesterolDR10624 50 mg LDL CholesterolDR10624 75mg LDL CholesterolDR10624 12.5 mg HDL CholesterolDR10624 25 mg HDL CholesterolDR10624 50 mg HDL CholesterolDR10624 75mg HDL CholesterolDR10624 12.5 mg Non-HDL CholesterolDR10624 25 mg Non-HDL CholesterolDR10624 50 mg Non-HDL CholesterolDR10624 75mg Non-HDL CholesterolDR10624 12.5 mg Lipoprotein-aDR10624 25 mg Lipoprotein-aDR10624 50 mg Lipoprotein-aDR10624 75mg Lipoprotein-aDR10624 12.5 mg VLDL CholesterolDR10624 25 mg VLDL CholesterolDR10624 50 mg VLDL CholesterolDR10624 75mg VLDL CholesterolDR10624 12.5 mg TriglyceridesDR10624 25 mg TriglyceridesDR10624 50 mg TriglyceridesDR10624 75mg TriglyceridesDR10624 12.5 mg Free Fatty AcidDR10624 25 mg Free Fatty AcidDR10624 50 mg Free Fatty AcidDR10624 75mg Free Fatty Acid
Change in Fasting Lipid Profile0.905 (0.817 to 1.002)0.932 (0.841 to 1.032)0.814 (0.732 to 0.905)0.850 (0.767 to 0.943)0.874 (0.732 to 1.044)1.017 (0.852 to 1.215)0.883 (0.735 to 1.061)0.928 (0.775 to 1.111)1.032 (0.895 to 1.190)1.025 (0.888 to 1.183)0.957 (0.828 to 1.105)0.974 (0.842 to 1.125)0.860 (0.760 to 0.973)0.899 (0.795 to 1.017)0.763 (0.671 to 0.867)0.817 (0.721 to 0.926)0.970 (0.617 to 1.526)1.116 (0.709 to 1.755)1.619 (1.023 to 2.564)1.991 (1.259 to 3.149)0.642 (0.393 to 1.047)0.440 (0.270 to 0.719)0.318 (0.193 to 0.525)0.300 (0.183 to 0.492)0.691 (0.486 to 0.983)0.460 (0.324 to 0.654)0.345 (0.240 to 0.495)0.393 (0.275 to 0.562)1.036 (0.653 to 1.644)0.911 (0.574 to 1.446)1.217 (0.764 to 1.940)0.953 (0.591 to 1.534)
SecondaryChange in Fasting Plasma Glucose (FPG)

the difference in LS Means FPG change from baseline compared with placebo

Time frame:
baseline through Day 85
Reported as:
Geometric least squares mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LDR10624 12.5mgDR10624 25mgDR10624 50mgDR10624 75mg
Change in Fasting Plasma Glucose (FPG)-0.023 (-0.873 to 0.827)0.305 (-0.553 to 1.164)-0.701 (-1.556 to 0.155)-0.302 (-0.879 to 0.815)
SecondaryChange in C-peptide

the difference in LS Means Ratio of C-peptide change from baseline compared with placebo

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · pmol/L
Change in C-peptide
pmol/LDR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
Change in C-peptide0.762 (0.534 to 1.089)0.850 (0.597 to 1.209)0.628 (0.438 to 0.899)0.676 (0.472 to 0.969)
SecondaryChange in Fasting Insulin

the difference in LS Means Ratio of fasting insulin change from baseline compared with placebo

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · pmol/L
Change in Fasting Insulin
pmol/LDR10624 12.5mgDR10624 25mgDR10624 50mgDR10624 75mg
Change in Fasting Insulin0.520 (0.359 to 0.752)0.636 (0.439 to 0.920)0.480 (0.329 to 0.700)0.589 (0.404 to 0.858)
SecondaryChange in Hemoglobin A1C

the difference in LS Means Ratio of Hemoglobin A1C change from baseline compared with placebo

Time frame:
baseline through Day 85(part 2)
Reported as:
Geometric least squares mean · mmol/mol
Change in Hemoglobin A1C
mmol/molDR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
Change in Hemoglobin A1C1.012 (0.948 to 1.080)0.998 (0.936 to 1.064)0.989 (0.926 to 1.055)1.013 (0.949 to 1.080)
SecondaryChange in Glucagon

the difference in LS Means Ratio fasting glucagon change from baseline compared with placebo

Time frame:
baseline through Day 85
Reported as:
Geometric least squares mean · ng/L
Change in Glucagon
ng/LDR10624 12.5mg Part 2DR10624 25mg Part 2DR10624 50mg Part 2DR10624 75mg Part 2
Change in Glucagon0.655 (0.194 to 2.206)0.238 (0.072 to 0.786)0.110 (0.033 to 0.372)0.080 (0.024 to 0.264)
SecondaryChange in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B)

The difference in LS Means Ratio HOMA-IR and HOMA-B change from baseline compared with placebo. HOMA-IR: (Fasting Insulin \[μU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5; HOMA-β: (20 × Fasting Insulin \[μU/mL\]) / (Fasting Glucose \[mmol/L\] - 3.5). For HOMA-IR: lower values indicate improved insulin sensitivity (less insulin resistance), representing a better outcome. For HOMA-B: higher values indicate enhanced pancreatic beta-cell function, representing a better outcome.

Time frame:
baseline through Day 85
Reported as:
Geometric least squares mean · index
Change in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B)
indexDR10624 12.5 mg part2 HOMA-IRDR10624 25 mg part2 HOMA-IRDR10624 50 mg part2 HOMA-IRDR10624 75mg part2 HOMA-IRDR10624 12.5 mg part2 HOMA-BDR10624 25 mg part2 HOMA-BDR10624 50 mg part2 HOMA-BDR10624 75mg part2 HOMA-B
Change in Homeostatic Model Assessment Index of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment Index of Beta-cell Function (HOMA-B)0.510 (0.326 to 0.797)0.660 (0.421 to 1.034)0.420 (0.267 to 0.662)0.579 (0.368 to 0.912)0.540 (0.286 to 1.020)0.504 (0.265 to 0.957)0.830 (0.433 to 1.591)0.612 (0.321 to 1.168)
SecondaryPercent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2

percentage change from baseline in hepatic fat fraction measured by MRI-PDFF in part 2. Percent change was calculated as \[(post-baseline value - baseline value) / baseline value\] × 100.

Time frame:
Baseline (screening) and Day 85 to Day 99 in Part 2
Reported as:
Mean · percent change of MRI-PDFF
Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2
percent change of MRI-PDFFDR10624 12.5mg part2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2Placebo part2
Percent Change From Baseline in Hepatic Fat Fraction Measured by MRI-PDFF in Part 2-51.88 ± 32.353-77.78 ± 14.473-78.95 ± 12.870-75.76 ± 22.654-26.27 ± 17.994
SecondaryPositive Rate of ADA

overall positive rate of ADA at EOS

Time frame:
from baseline to the end of the study, up to Day29s (part1, part3), up to Day106s (part2)
Reported as:
Count of participants · Participants
Positive Rate of ADA
ParticipantsDR10624 0.5mg Part 1DR10624 1.5mg part1DR10624 4.5mg part1DR10624 12.5mg part1DR10624 25mg part1DR10624 50mg part1DR10624 65mg part1DR10624 90mg part1DR10624 120mg part1DR10624 12.5mg Part 2DR10624 25mg part2DR10624 50mg part2DR10624 75mg part2DR10624 25mg part3DR10624 65mg part3DR10624 90mg part3
Positive Rate of ADA0000001101000000
SecondaryContinuous Glucose Monitoring Outcome

Individual results of CGM endpoints and results are presented by subject in the listing contained in the CSR attachment.

Time frame:
from baseline to D79(part 2)

Results for this outcome have not been posted.

SecondaryChange in Fibrosis 4 Index

Change in Fibrosis 4 Index from baseline. Fibrosis 4 Index (FIB-4) is a continuous calculated score for liver fibrosis staging, derived from the formula: FIB-4 = (age \[years\] × AST \[U/L\]) / (platelet count \[10\^9/L\] × √ALT \[U/L\]), which can be used to identify patients with a low probability of advanced fibrosis. The theoretical minimum value is 0, and there is no predefined maximum value (the score is open-ended). Lower values indicate a lower probability of advanced liver fibrosis, representing a better outcome. For clinical interpretation, commonly used cutoff values are as follows: FIB-4 \< 1.3: low probability of advanced liver fibrosis (better outcome); 1.3 ≤ FIB-4 \< 3.25: indeterminate fibrosis stage; FIB-4 ≥ 3.25: high probability of advanced liver fibrosis (worse outcome).

Time frame:
from baseline to D85(part 2)
Reported as:
Mean · scores on a scale
Change in Fibrosis 4 Index
scores on a scaleDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Fibrosis 4 Index-0.09 ± 0.125-0.14 ± 0.224-0.06 ± 0.169-0.26 ± 0.437-0.14 ± 0.098
SecondaryChange in Non-Alcoholic Fatty Liver Disease Fibrosis Score

The Non-Alcoholic Fatty Liver Disease Fibrosis Score (NFS) is a derived non-invasive fibrosis score calculated as -1.675 + 0.037 × age (year) + 0.094 × BMI (kg/m\^2) + 1.13 × impaired fasting glucose or diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio - 0.013 × platelet count (×10\^9/L) - 0.66 × albumin (g/dL). This score does not have a fixed theoretical minimum or maximum; higher values indicate greater likelihood of advanced fibrosis

Time frame:
from baseline to D85 (part 2)
Reported as:
Mean · units on a scale
Change in Non-Alcoholic Fatty Liver Disease Fibrosis Score
units on a scaleDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Non-Alcoholic Fatty Liver Disease Fibrosis Score0.14 ± 0.226-0.13 ± 0.5630.31 ± 0.7280.10 ± 0.330-0.34 ± 0.619
SecondaryChange in Alanine Aminotransferase

change in Alanine Aminotransferase from baseline

Time frame:
from baseline to D85 (part 2)
Reported as:
Mean · IU/L
Change in Alanine Aminotransferase
IU/LDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Alanine Aminotransferase-5.6 ± 10.501.3 ± 12.04-0.8 ± 6.86-8.6 ± 22.32-5.9 ± 9.58
SecondaryChange in Aspartate Aminotransferase

change in Aspartate Aminotransferase from baseline

Time frame:
from baseline to D85 (part 2)
Reported as:
Mean · IU/L
Change in Aspartate Aminotransferase
IU/LDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Aspartate Aminotransferase-4.89 ± 6.451-5.61 ± 7.889-4.25 ± 5.898-11.25 ± 20.289-4.00 ± 6.083
SecondaryChange in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

change in Partial area glucose levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

Time frame:
from 0 to 4 hours on D79
Reported as:
Mean · h*mmol/L
Change in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
h*mmol/LDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Partial Area Glucose Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)-2.372 ± 3.46130.670 ± 1.6414-0.614 ± 1.51571.076 ± 2.32290.502 ± 1.4597
SecondaryChange in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

change in Partial area insulin levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

Time frame:
from 0 to 4 hours on D79
Reported as:
Mean · h*pmol/L
Change in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
h*pmol/LDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Partial Area Insulin Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)-543.332 ± 741.3500-213.593 ± 907.3172-925.121 ± 724.0457-245.586 ± 676.1720349.545 ± 810.0063
SecondaryChange in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

change in Partial area C-peptide levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

Time frame:
from 0 to 4 hours on D79
Reported as:
Mean · h*pmol/L
Change in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
h*pmol/LDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Partial Area C-peptide Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)-1607.643 ± 2296.2616175.979 ± 2712.0876-1526.766 ± 1958.0598-934.313 ± 1252.3779277.850 ± 1407.1687
SecondaryChange in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)

change in Partial area glucagon levels versus time curve from time 0 to 4 hours (△AUC0-4h) from baseline

Time frame:
from 0 to 4 hours on D79
Reported as:
Mean · h*ng/mL
Change in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)
h*ng/mLDR10624 12.5 mg part2DR10624 25 mg part2DR10624 50 mg part2DR10624 75mg part2Placebo part2
Change in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)13.768 ± 25.2027-16.809 ± 19.2574-15.879 ± 26.3393-67.753 ± 81.4642-21.713 ± 54.4851
SecondaryChange Percentage of Time Spent of Glucose in Target Range 3.9 to 10 mmol/L (TIR), Time Above Target Range (TAR), Time Below Target Range (TBR), 24-hour Mean Glucose, and Glucose Variability

statistical analysis of TIR, TAR, TBR, 24-hour mean glucose and glucose variability was not performed due to small sample size

Time frame:
baseline through Day 85(part 2)

Results for this outcome have not been posted.

Adverse events

Collected over from enrollment until end of follow-up, part1 up to 29 days, part2 up to 106 days, part3 up to 29 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-ascending Dose:Part1:DR10624 0.5mg0/4 (0%)0/4 (0%)0/4 (0%)
Single-ascending Dose:Part1:DR10624 1.5mg0/6 (0%)0/6 (0%)0/6 (0%)
Single-ascending Dose:Part1:DR10624 4.5mg0/6 (0%)0/6 (0%)0/6 (0%)
Single-ascending Dose:Part1:DR10624 12.5mg0/6 (0%)0/6 (0%)4/6 (66.7%)
Single-ascending Dose:Part1:DR10624 25mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Single-ascending Dose:Part1:DR10624 50mg0/6 (0%)0/6 (0%)6/6 (100%)
Single-ascending Dose:Part1:DR10624 65mg0/6 (0%)0/6 (0%)6/6 (100%)
Single-ascending Dose:Part1:DR10624 90mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Single-ascending Dose:Part1:DR10624 120mg0/6 (0%)0/6 (0%)5/6 (83.3%)
Single-ascending Dose:Part1:Placebo0/16 (0%)1/16 (6.3%)1/16 (6.3%)
Multiple-ascending Dose:Part2:DR10624 12.5mg0/10 (0%)0/10 (0%)10/10 (100%)
Multiple-ascending Dose:Part2:DR10624 25mg0/10 (0%)0/10 (0%)10/10 (100%)
Multiple-ascending Dose:Part2:DR10624 50mg0/11 (0%)0/11 (0%)11/11 (100%)
Multiple-ascending Dose:Part2:DR10624 75mg0/10 (0%)0/10 (0%)10/10 (100%)
Multiple-ascending Dose:Part2:Placebo0/8 (0%)0/8 (0%)6/8 (75%)
Single-ascending Dose:Part 3:DR10624 25mg0/10 (0%)0/10 (0%)3/10 (30%)
Single-ascending Dose:Part 3:DR10624 65mg0/10 (0%)0/10 (0%)6/10 (60%)
Single-ascending Dose:Part 3:DR10624 90mg0/10 (0%)0/10 (0%)7/10 (70%)
Single-ascending Dose:Part3:Placebo0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventSingle-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part 3:DR10624 25mgSingle-ascending Dose:Part 3:DR10624 65mgSingle-ascending Dose:Part 3:DR10624 90mgSingle-ascending Dose:Part3:Placebo
intentional overdoseInfections and infestations0/40/60/60/60/60/60/60/60/61/160/100/100/110/100/80/100/100/100/6
Most frequent other events
Most frequent other events
EventSingle-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part 3:DR10624 25mgSingle-ascending Dose:Part 3:DR10624 65mgSingle-ascending Dose:Part 3:DR10624 90mgSingle-ascending Dose:Part3:Placebo
NauseaGastrointestinal disorders0/40/60/61/62/64/63/64/64/60/163/102/1011/119/102/80/101/106/100/6
VomitingGastrointestinal disorders0/40/60/61/60/62/62/62/63/60/162/103/108/116/100/80/100/100/100/6
Decreased appetiteGastrointestinal disorders0/40/60/60/60/60/60/60/60/60/161/102/105/116/101/80/103/106/100/6
Injection site erythemaSurgical and medical procedures0/40/60/60/62/62/63/61/63/61/164/105/105/116/100/80/100/100/100/6
Increased appetiteGastrointestinal disorders0/40/60/62/61/63/62/60/60/60/163/103/102/114/100/83/100/102/100/6
DiarrhoeaGastrointestinal disorders0/40/60/60/60/60/60/60/60/60/161/101/103/114/103/80/100/100/100/6
Urinary tract infectionInfections and infestations0/40/60/60/60/60/60/60/60/60/160/100/100/110/100/80/103/101/102/6
HypertriglyceridaemiaMetabolism and nutrition disorders0/40/60/60/60/60/60/60/60/60/160/100/100/110/100/80/100/100/102/6
Blood uric acid increasedRenal and urinary disorders0/40/60/60/60/60/60/60/60/60/160/100/100/110/100/80/102/101/101/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Single-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part3:DR10624 25mgSingle-ascending Dose:Part3:DR10624 65mgSingle-ascending Dose:Part3:DR10624 90mgSingle-ascending Dose:Part3:PlaceboTotal
Mean23.8 ± 2.3627.3 ± 7.4229.8 ± 10.1726.5 ± 5.2427.0 ± 13.4828.8 ± 13.6425.0 ± 5.9032.0 ± 15.7545.3 ± 10.3934.1 ± 11.7136.3 ± 10.6437.8 ± 7.1141.7 ± 8.3042.8 ± 14.2046.1 ± 11.8934.4 ± 6.7931.7 ± 5.3837.3 ± 5.4235.3 ± 8.3134.9 ± 11.12
Sex: Female, Male
Sex: Female, Male(Participants)Single-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part3:DR10624 25mgSingle-ascending Dose:Part3:DR10624 65mgSingle-ascending Dose:Part3:DR10624 90mgSingle-ascending Dose:Part3:PlaceboTotal
Female3311365341034744344678
Male135530132676464766075
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-ascending Dose:Part1:DR10624 0.5mgSingle-ascending Dose:Part1:DR10624 1.5mgSingle-ascending Dose:Part1:DR10624 4.5mgSingle-ascending Dose:Part1:DR10624 12.5mgSingle-ascending Dose:Part1:DR10624 25mgSingle-ascending Dose:Part1:DR10624 50mgSingle-ascending Dose:Part1:DR10624 65mgSingle-ascending Dose:Part1:DR10624 90mgSingle-ascending Dose:Part1:DR10624 120mgSingle-ascending Dose:Part1:PlaceboMultiple-ascending Dose:Part2:DR10624 12.5mgMultiple-ascending Dose:Part2:DR10624 25mgMultiple-ascending Dose:Part2:DR10624 50mgMultiple-ascending Dose:Part2:DR10624 75mgMultiple-ascending Dose:Part2:PlaceboSingle-ascending Dose:Part3:DR10624 25mgSingle-ascending Dose:Part3:DR10624 65mgSingle-ascending Dose:Part3:DR10624 90mgSingle-ascending Dose:Part3:PlaceboTotal
American Indian or Alaska Native00000000000000000000
Asian000200000221021101010646
Native Hawaiian or Other Pacific Islander002000100141220000013
Black or African American00000000000000000000
White3543663561046764000078
More than one race10010010010020100007
Unknown or Not Reported01000011020200200009
08

Study locations

1 site
  • New Zealand Clinical Research
    Christchurch, Canterbury 8011, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Oct 2024, 27 months.

Results were first posted in Oct 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2022
First posted
May 18, 2022
StartActual
Jun 22, 2022
Primary completionActual
Oct 10, 2024
CompletionActual
Jan 31, 2025
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Interventions
Arms added: Single-ascending dose:Part3:DR10624·Single-ascending dose:Part3:placebo
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Number of participants with one or more treatment-emergent adverse event (TEAE), serious adverse event (SAE) and adverse event of special interest (AESI).Now Assess the Safety and TolerabilityTime frame: baseline through day 29(part 1)or day 106(part 2) → Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)
Oct 19, 2026
Documents
Secondary outcomes
23 edited, 7 added, 7 more
What changed in the outcomes
  • EditedArea underUnder the serum concentration versus time curveSerum Concentration Versus Time Curve (AUC)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3)or day 106 (part 2)
  • EditedMaximum observed serum concentrationObserved Serum Concentration (Cmax)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
  • EditedTime to reach maximum observed serum concentrationReach Maximum Observed Serum Concentration (Tmax)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2).
  • EditedTerminal elimination halfElimination Half-life (t1/2)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2).
  • EditedApparent clearance after extravascular administrationClearance After Extravascular Administration (CL/F)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
  • EditedApparent volumeVolume of distribution duringDistribution During the terminal elimination phase after extravascular administrationTerminal Elimination Phase After Extravascular Administration (Vz/F)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
  • EditedchangeChange in body weightBody WeightTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangeChange in adiponectinAdiponectinTime frame: baseline through Day 85
  • EditedchangeChange in BMIFasting Lipid ProfileTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangeChange in waist circumferenceFasting InsulinTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangeChange in fasting lipid profileGlucagonTime frame: baseline through Day 85
  • EditedchangeChange in fasting plasma glucoseFasting Plasma Glucose (FPG)Time frame: baseline through Day 85
  • EditedchangeChange in HbA1cC-peptideTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangeChange in fasting insulinHemoglobin A1CTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangeChange in glucagonFibrosis 4 IndexTime frame: baseline through Day 85 → from baseline to D85(part 2)
  • EditedchangeChange in homeostatic model assessment indexHomeostatic Model Assessment Index of insulin resistanceInsulin Resistance (HOMA-IR) and homeostatic model assessment indexHomeostatic Model Assessment Index of betaBeta-cell functionFunction (HOMA-B)Time frame: baseline through Day 85
  • Editedchange in Partial area glucose level versus time curve from timeArea Under the Plasma Concentration-Time Curve From Time 0 to 4 hoursInfinity (△AUC0-4hinf)Time frame: baseline through Day 85 → baseline through day29(part 1 and part 3 )
  • EditedchangeChange in Partial area insulin level versus time curve from timeArea Glucose Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
  • EditedchangeChange in Partial area C-peptide level versus time curve from timeArea Insulin Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
  • EditedchangeChange in Partial area glucagon level versus time curve from timeArea C-peptide Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
  • Editedchange percentageChange Percentage of time spentTime Spent of glucoseGlucose in target rangeTarget Range 3.9 to 10 mmol/L (TIR), time above target rangeTime Above Target Range (TAR), time below target rangeTime Below Target Range (TBR), 24-hour mean glucoseMean Glucose, and glucose variabilityGlucose VariabilityTime frame: baseline through Day 85 → baseline through Day 85(part 2)
  • EditedchangePercent Change From Baseline in hepatic fat fraction measuredHepatic Fat Fraction Measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF ) in partPart 2Time frame: baseline through Day 85 → Baseline (screening) and Day 85 to Day 99 in Part 2
  • EditedChange in Non-Alcoholic Fatty Liver Disease Fibrosis 4 score (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS)ScoreTime frame: baseline through Day 85 → from baseline to D85 (part 2)
  • Addedthe Difference in LS Means BMI Change From Baseline Compared With PlaceboTime frame: baseline through Day 85(part 2)
  • Addedthe Difference in LS Means Waist Circumference Change From Baseline Compared With PlaceboTime frame: baseline through Day 85(part 2)
  • AddedPositive Rate of ADATime frame: from baseline to the end of the study, up to Day29s (part1, part3), up to Day106s (part2)
  • AddedContinuous Glucose Monitoring OutcomeTime frame: from baseline to D79(part 2)
  • AddedChange in Alanine AminotransferaseTime frame: from baseline to D85 (part 2)
  • AddedChange in Aspartate AminotransferaseTime frame: from baseline to D85 (part 2)
  • AddedChange in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)Time frame: from 0 to 4 hours on D79
  • …and 7 more, on the record history on ClinicalTrials.gov ↗
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Number of participants with one or more treatment-emergent adverse event (TEAE), serious adverse event (SAE) and adverse event of special interest (AESI).Now Assess the Safety and TolerabilityTime frame: baseline through day 29(part 1)or day 106(part 2) → Baseline through Day 29 (Part 1 & Part 3); Pre-final dose on Day 78 through Day 106 (Part 2)
    Secondary outcomes 23 edited, 7 added, 7 more
    What changed in the outcomes
    • EditedArea underUnder the serum concentration versus time curveSerum Concentration Versus Time Curve (AUC)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3)or day 106 (part 2)
    • EditedMaximum observed serum concentrationObserved Serum Concentration (Cmax)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
    • EditedTime to reach maximum observed serum concentrationReach Maximum Observed Serum Concentration (Tmax)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2).
    • EditedTerminal elimination halfElimination Half-life (t1/2)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2).
    • EditedApparent clearance after extravascular administrationClearance After Extravascular Administration (CL/F)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
    • EditedApparent volumeVolume of distribution duringDistribution During the terminal elimination phase after extravascular administrationTerminal Elimination Phase After Extravascular Administration (Vz/F)Time frame: baseline through day 29(part 1)or day 106(part 2) → baseline through day 29 (part 1and part 3) or day 106 (part 2)
    • EditedchangeChange in body weightBody WeightTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangeChange in adiponectinAdiponectinTime frame: baseline through Day 85
    • EditedchangeChange in BMIFasting Lipid ProfileTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangeChange in waist circumferenceFasting InsulinTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangeChange in fasting lipid profileGlucagonTime frame: baseline through Day 85
    • EditedchangeChange in fasting plasma glucoseFasting Plasma Glucose (FPG)Time frame: baseline through Day 85
    • EditedchangeChange in HbA1cC-peptideTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangeChange in fasting insulinHemoglobin A1CTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangeChange in glucagonFibrosis 4 IndexTime frame: baseline through Day 85 → from baseline to D85(part 2)
    • EditedchangeChange in homeostatic model assessment indexHomeostatic Model Assessment Index of insulin resistanceInsulin Resistance (HOMA-IR) and homeostatic model assessment indexHomeostatic Model Assessment Index of betaBeta-cell functionFunction (HOMA-B)Time frame: baseline through Day 85
    • Editedchange in Partial area glucose level versus time curve from timeArea Under the Plasma Concentration-Time Curve From Time 0 to 4 hoursInfinity (△AUC0-4hinf)Time frame: baseline through Day 85 → baseline through day29(part 1 and part 3 )
    • EditedchangeChange in Partial area insulin level versus time curve from timeArea Glucose Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
    • EditedchangeChange in Partial area C-peptide level versus time curve from timeArea Insulin Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
    • EditedchangeChange in Partial area glucagon level versus time curve from timeArea C-peptide Levels Versus Time Curve From Time 0 to 4 hoursHours (△AUC0-4h)Time frame: baseline through Day 85 → from 0 to 4 hours on D79
    • Editedchange percentageChange Percentage of time spentTime Spent of glucoseGlucose in target rangeTarget Range 3.9 to 10 mmol/L (TIR), time above target rangeTime Above Target Range (TAR), time below target rangeTime Below Target Range (TBR), 24-hour mean glucoseMean Glucose, and glucose variabilityGlucose VariabilityTime frame: baseline through Day 85 → baseline through Day 85(part 2)
    • EditedchangePercent Change From Baseline in hepatic fat fraction measuredHepatic Fat Fraction Measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF ) in partPart 2Time frame: baseline through Day 85 → Baseline (screening) and Day 85 to Day 99 in Part 2
    • EditedChange in Non-Alcoholic Fatty Liver Disease Fibrosis 4 score (FIB-4) and non-alcoholic fatty liver disease fibrosis score (NFS)ScoreTime frame: baseline through Day 85 → from baseline to D85 (part 2)
    • Addedthe Difference in LS Means BMI Change From Baseline Compared With PlaceboTime frame: baseline through Day 85(part 2)
    • Addedthe Difference in LS Means Waist Circumference Change From Baseline Compared With PlaceboTime frame: baseline through Day 85(part 2)
    • AddedPositive Rate of ADATime frame: from baseline to the end of the study, up to Day29s (part1, part3), up to Day106s (part2)
    • AddedContinuous Glucose Monitoring OutcomeTime frame: from baseline to D79(part 2)
    • AddedChange in Alanine AminotransferaseTime frame: from baseline to D85 (part 2)
    • AddedChange in Aspartate AminotransferaseTime frame: from baseline to D85 (part 2)
    • AddedChange in Partial Area Glucagon Levels Versus Time Curve From Time 0 to 4 Hours (△AUC0-4h)Time frame: from 0 to 4 hours on D79
    • …and 7 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arms added: Single-ascending dose:Part3:DR10624·Single-ascending dose:Part3:placebo
    + 5 other changes: index terms, verification date, oversight details, criteria formatting and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05378893
Responsible party
Sponsor
First posted
May 18, 2022
Start date
Jun 22, 2022
Primary completion
Oct 10, 2024
Completion
Jan 31, 2025
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Alexandra Cole, DHPharm
principal investigator · New Zealand Clinical Research (NZCR)
Yanshan Huang, PhD
study chair · Zhejiang Doer Biologics Co., Ltd.
Yongliang Fang, PhD
study director · Zhejiang Doer Biologics Co., Ltd.
Junfang Xu, MD
study director · Huadong Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DR10624

Start the discussion